

Run on: July 1, 2003, 14:30:42 ; Search time 367 Seconds

(without alignments)
9314.805 Million cell updates/sec

Title: US-10-010-742-305
Perfect score: 1518

Sequence: 1 atggagccctcctgctca.....ttgcaaaaagtctgctaa 1518

Scoring table: IDENTITY_NUC

Searched: . 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 08
Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_101002:*

121: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1980.DAT.*
122: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1981.DAT.*
123: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1982.DAT.*
124: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1983.DAT.*
125: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1984.DAT.*
126: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1985.DAT.*
127: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1986.DAT.*
128: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1987.DAT.*
129: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1988.DAT.*
130: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1989.DAT.*
131: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1990.DAT.*
132: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1991.DAT.*
133: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1992.DAT.*
134: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1993.DAT.*
135: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1994.DAT.*
136: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1995.DAT.*
137: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1996.DAT.*
138: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1997.DAT.*
139: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1998.DAT.*
140: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA1999.DAT.*
141: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA2000.DAT.*
142: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA2001A.DAT.*
143: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA2001B.DAT.*
144: /SIDS2.gcgcdatta.genseeq/genseeqn-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB | ID | Description |
|------------|--------|-------------|--------|----|-----------|-------------------|
| 1 | 1518 | 100.0 | 2015 | 24 | ABD24015 | Human drug metabo |
| 2 | 1516.4 | 99.9 | 2020 | 24 | ABR33550 | cDNA encoding hum |
| 3 | 1028.8 | 67.8 | 1566 | 22 | ABD019946 | Human drug metabo |
| 4 | 671.2 | 44.2 | 2343 | 22 | AA521297 | Human cDNA sequen |
| 5 | 671.2 | 44.2 | 2381 | 24 | ABR63921 | cDNA encoding hum |
| 6 | 671.2 | 44.2 | 2416 | 22 | ABD09941 | Human drug metabo |
| 7 | 658.2 | 43.4 | 2337 | 24 | ABR52898 | cDNA encoding hum |
| 8 | 651 | 42.9 | 2356 | 22 | AA199563 | Human expressed p |
| 9 | 651 | 42.9 | 2356 | 22 | ABR06504 | Human cDNA seq ID |

| | | | | | | |
|----|-------|------|-------|----|----------|---------------------|
| 10 | 651 | 42.9 | 23.56 | 22 | AAS40801 | CDNA encoding novel |
| 11 | 651 | 42.9 | 23.56 | 22 | AAS29859 | CDNA encoding for |
| 12 | 651 | 42.9 | 23.56 | 22 | AAS29392 | Human endocrine po |
| 13 | 651 | 42.9 | 23.56 | 22 | AAS34859 | CDNA encoding novel |
| 14 | 576 | 37.9 | 11.66 | 23 | AAS70309 | CDNA encoding novel |
| 15 | 539 | 35.5 | 9.40 | 21 | AAC79474 | CDNA sequence of h |
| 16 | 539 | 35.5 | 9.40 | 24 | AAC79018 | Human breast tumou |
| 17 | 528.8 | 34.8 | 25.76 | 24 | ABN95640 | Gene #2138 used to |
| 18 | 528.8 | 34.8 | 25.76 | 24 | ABK50069 | CDNA encoding human |
| 19 | 528.8 | 34.8 | 25.76 | 24 | ABK68591 | Kidney cancer rela |
| 20 | 524 | 34.3 | 18.72 | 24 | ABK50070 | CDNA encoding human |
| 21 | 521.2 | 34.3 | 5.35 | 22 | AAL23934 | Human breast cancer |
| 22 | 517.6 | 34.1 | 7.60 | 22 | AAL22366 | Human breast cancer |
| 23 | 511.8 | 33.7 | 5.35 | 22 | ALL15081 | Human breast cancer |
| 24 | 511.2 | 33.7 | 21.16 | 24 | ABK50068 | CDNA encoding novel |
| 25 | 504.8 | 33.7 | 24.62 | 24 | ABK63715 | Human breast cancer |
| 26 | 503.6 | 33.2 | 5.35 | 22 | AAU21747 | Human breast cancer |
| 27 | 496.4 | 32.7 | 5.26 | 22 | AAL23827 | Human breast cancer |
| 28 | 494.8 | 32.6 | 1.763 | 24 | ABN95112 | Gene #1610 used to |
| 29 | 494.8 | 32.6 | 1.763 | 24 | ABL68871 | Kidney cancer rela |
| 30 | 494.8 | 32.6 | 1.763 | 24 | ABL68859 | Kidney cancer rela |
| 31 | 494.8 | 32.6 | 1.763 | 24 | ABL68881 | Kidney cancer rela |
| 32 | 492.8 | 32.5 | 4.98 | 22 | AAH53549 | Human breast tumor |
| 33 | 490.4 | 32.3 | 5.34 | 22 | AAU22422 | Human breast cancer |
| 34 | 489.8 | 32.3 | 9.33 | 20 | AA384701 | CDNA encoding human |
| 35 | 489.8 | 32.3 | 9.33 | 21 | AACT9430 | CDNA sequence of h |
| 36 | 489.8 | 32.3 | 9.33 | 24 | ABK28974 | Human breast tumor |
| 37 | 484.6 | 31.9 | 4.123 | 24 | ABK50067 | CDNA encoding novel |
| 38 | 480.4 | 31.6 | 5.39 | 22 | AAU12371 | Human breast cancer |
| 39 | 478.2 | 31.5 | 5.35 | 22 | AAU24012 | Human breast cancer |
| 40 | 462.4 | 30.5 | 7.57 | 22 | AAU24582 | Human breast cancer |
| 41 | 456.2 | 30.1 | 6.58 | 22 | AAU13738 | Human breast cancer |
| 42 | 455.8 | 30.0 | 6.41 | 22 | AAU13497 | Human breast cancer |
| 43 | 432.8 | 27.5 | 4.63 | 22 | AAU13553 | Human breast cancer |
| 44 | 417 | 27.5 | 20.84 | 24 | ABU67800 | Oesophagus cancer |
| 45 | 409.2 | 27.0 | 4.91 | 22 | AAU14974 | Human breast cancer |

ALIGNMENTS

| | |
|--------|---|
| XX | RESULT_1 |
| XX | ID AAD24015 |
| XX | AAD24015 standard; cDNA; 2015 BP. |
| XX | AC AAD24015; |
| XX | DT 26-MAR-2002 (first entry) |
| XX | DE Human drug metabolising enzyme (DME)-10 cDNA. |
| XX | KW Human; drug metabolising enzyme; DME-10; autoimmune; inflammatory; KW gastric proliferative; developmental; endocrine; eye; metabolic; AIDS; KW gastrointestinal disorder; liver disorder; cancer; arteriosclerosis; KW adult respiratory distress syndrome; anaemia; epilepsy; hypothyroidism; KW glaucoma; pituitary; diabetes; hypogonadism; conjunctivitis; KW haemochromatosis; hypercholesterolaemia; gastritis; KW peptic ulcer; hepatitis; gene therapy; ss. |
| XX | OS Homo sapiens. |
| XX | Key Location/Qualifiers |
| FT CDS | 117..1634 |
| FT FT | /*tag= a |
| FT FT | /product= "Drug metabolising enzyme-10" |
| FT FT | 117..209 |
| FT FT | /*tag= b |
| FT FT | 210..1631 |
| FT FT | /*tag= c |
| FT FT | /product= "Mature drug metabolising enzyme-10" |
| XX | NC0200190334-A2. |
| XX | PN |
| XX | XX |

PD 29-NOV-2001.
 XX 25-MAY-2001; 2001WO-US17150.
 PF 25-MAY-2000; 2000US-207901P.
 PR 01-JUN-2000; 2000US-20883P.
 PR 07-JUN-2000; 2000US-209861P.
 PR 15-JUN-2000; 2000US-211825P.
 PR 22-JUN-2000; 2000US-213744P.
 XX (INCY-) INCYTE GENOMICS INC.
 PA Yue H, Sanjanvala MS, Baughn KR, Gandhi AR, Ring HZ, Elliott V;
 PI Halia NK, Yang J, Khan FA, Ramkumar J, Tang YP, Hafalla A, Lal P;
 PI Nguyen DB, Yao MG, Lee EA, Tribouley CM, Patterson C, Lu Y;
 PI Butford N, Ding L, Bruns CM, Kearney L, Reddy K;
 XX WPI; 2002-097650/13.
 DR P-PSDB; AAE14447.
 XX New human drug metabolizing enzymes and polynucleotides encoding the
 PT enzyme for diagnosing, preventing or treating cell proliferative,
 PT autoimmune/inflammatory, endocrine, eye, metabolic and gastrointestinal
 PT disorders
 PS Claim 5; Page 155-156; 158pp; English.
 XX The present sequence is human drug metabolizing enzyme (DME)-10 cDNA.
 CC DME polypeptide, polynucleotide and modulators are useful for
 CC diagnosis, treatment and prevention of autoimmune/inflammatory,
 CC cell proliferative, developmental, endocrine, eye, metabolic,
 CC and gastrointestinal disorders, including liver disorders.
 CC The autoimmune/inflammatory disorders treatable include
 CC AIDS, adult respiratory distress syndrome, Addison's disease,
 CC allergies, anaemia, asthma, atherosclerosis, osteoporosis, autoimmune
 CC haemolytic anaemia, autoimmune thyroiditis, Crohn's disease, atopic
 CC dermatitis, diabetic mellitus, Graves' disease, glomerulonephritis,
 CC rheumatoid arthritis, scleroderma, systemic lupus erythematosus,
 CC systemic sclerosis, ulcerative colitis, haemodialysis and ureitis,
 CC viral, bacterial, fungal, parasitic, protozoal, helminthic infections
 CC and trauma, and cell proliferative disorders such as cancer, actinic
 CC keratosis, arteriosclerosis, atherosclerosis, bursitis, arthritis,
 CC hepatitis and psoriasis. Developmental disorders include anaemia, renal
 CC tubular acidosis, epilepsy, hypothyroidism and cataract, and endocrine
 CC disorders include disorders of hypothalamus and pituitary, disorders
 CC associated with hypopituitarism, including sarcoidosis, diabetes
 CC insipidus, hypogonadism, disorders associated with hypothyroidism
 CC including goitre, acute thyroiditis, Graves' disease, disorders
 CC associated with hyperparathyroidism, pancreatic disorders such as type I
 CC or type II diabetes mellitus, disorders associated with adrenals such as
 CC hyperplasia, Cushing's disease, endometriosis, infertility,
 CC hypergonadal disorders, and gynaecomastia. Eye disorders include
 CC conjunctivitis, keratitis, glaucoma and macular degeneration, and
 CC metabolic disorders include diabetes, cystic fibrosis, goitre, and
 CC hypercholesterolaemia, hypoglycaemia, hyperlipidaemia, lysosomal storage
 CC diseases, obesity, phenylketonuria and hypocalcaemia. Also the molecules
 CC are useful for treating gastrointestinal disorders such as dysphagia,
 CC gastritis, peptic ulcer, cholelithiasis, cirrhosis, hepatitis,
 CC thrombosis and hepatic tumours. The DME polypeptide is also useful for
 CC screening its agonist or antagonist.
 XX Sequence 2015 BP; 570 A; 487 C; 410 G; 548 T; 0 other;
 Query Match 100.0%; Score 1518; DB 24; Length 2015;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1518; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ATGAGCCCTCTGCTGCTTCAAGTAATCAGTGTGACAGAGAGAGATGATGTC 60
 DB 117 ATGAGCCCTCTGCTGCTTCAAGTAATCAGTGTGACAGAGAGAGATGATGTC 176
 QY 61 TGCATGCTCTGCTGCTTCAAGTAATCAGTGTGACAGAGAGAGATGATGTC 120

DB 177 TGCATGCTCTGCTGCTTCAAGTAATCAGTGTGACAGAGAGAGATGATGTC 236
 QY 121 AGAGCCCTGCACTGCTTCCGCAACCCCTGCCACAGGCTTCTAGGCCAAGAAGTT 180
 DB 237 AGAGCCCTGCACTGCTTCCGCAACCCCTGCCACAGGCTTCTAGGCCAAGAAGTT 296
 QY 181 TACCAGTAAAGAGTTGAGTGTATCATATAGCTGATGAAATAATCCATGCTGCTT 240
 DB 297 TACCAGTAAAGAGTTGAGTGTATCATATAGCTGATGAAATAATCCATGCTGCTT 356
 QY 241 CCTGTGAGGTTGACCCCTTACAGATGCTTCAAGTGTGATGACCCAGATGATGCCAAG 300
 DB 357 CCTGTGAGGTTGACCCCTTACAGATGCTTCAAGTGTGATGACCCAGATGATGCCAAG 416
 QY 301 ATTCTCTGAAAGACAGATCCCAAAAGTCTGTAGCCCAAAATCCTGATTCCTGG 360
 DB 417 ATTCTCTGAAAGACAGATCCCAAAAGTCTGTAGCCCAAAATCCTGATTCCTGG 476
 QY 361 GTTGTGAGGACTTGTGACCCCTGATGCTTCAATGAAAGACCCGACAGATGTTG 420
 DB 477 GTTGTGAGGACTTGTGACCCCTGATGCTTCAATGAAAGACCCGACAGATGTTG 536
 QY 421 AAACCTGCTCAACATCAGATCTGAAAATATTCATCACCATGATGTGAGAGTGT 480
 DB 537 AAACCTGCTCAACATCAGATCTGAAAATATTCATCACCATGATGTGAGAGTGT 596
 QY 481 CGATGATGCTGAACAAATGGAGAGACGATGCTGCCAAATCTACGCTGTGAGTCTT 540
 DB 597 CGATGATGCTGAACAAATGGAGAGACGATGCTGCCAAATCTACGCTGTGAGTCTT 656
 QY 541 CAACATGCTCCCTGATGACCCCTGAGACATCATGAGTGTGCTTACGACACAGGCG 600
 DB 657 CAACATGCTCCCTGATGACCCCTGAGACATCATGAGTGTGCTTACGACACAGGCG 716
 QY 601 AGCATCCAGTTGACAGATGACCTGAGTACATACCTGAAAGAGTTCACCTTAGCAA 660
 DB 717 AGCATCCAGTTGACAGATGACCTGAGTACATACCTGAAAGAGTTCACCTTAGCAA 776
 QY 661 ATTCGCAACGCGCATGAAATTTTACATACACAGACCTGTTTCAATTCAGC 720
 DB 777 ATTCGCAACGCGCATGAAATTTTACATACACAGACCTGTTTCAATTCAGC 836
 QY 721 TCTCAAGGCCAAATCTTTTAAATTTAAACAAGACTTCATGCTCAGAGAAAGTA 780
 DB 837 TCTCAAGGCCAAATCTTTTAAATTTAAACAAGACTTCATGCTCAGAGAAAGTA 896
 QY 781 ATCCAGAGCCGGAAGAGTCTCTTAAGGATTAAGTAAACAAGATCTACTCAGAAAAG 840
 DB 897 ATCCAGAGCCGGAAGAGTCTCTTAAGGATTAAGTAAACAAGATCTACTCAGAAAAG 956
 QY 841 CGCTGGGATTTTCTGGACATCTTTGAGTGCCAAAGCGAAACCCAAAGATTTCT 900
 DB 957 CGCTGGGATTTTCTGGACATCTTTGAGTGCCAAAGCGAAACCCAAAGATTTCT 1016
 QY 901 GAAGCAGATCCAGGCTGGAAGTGAAGTAAAGCTTAAGTGTGAGGATGACACCATCC 960
 DB 1017 GAAGCAGATCCAGGCTGGAAGTGAAGTAAAGCTTAAGTGTGAGGATGACACCATCC 1076
 QY 961 AGTGTATCTCTGATGATCTTACTGCTTGCAAAAGTACCTGAGCATCAGAGAGATGC 1020
 DB 1077 AGTGTATCTCTGATGATCTTACTGCTTGCAAAAGTACCTGAGCATCAGAGAGATGC 1136
 QY 1021 CGAGTGAATCAGGGAATCTCTAGGAGATGGTCTTATTTACTGGAACACTGTAGC 1080
 DB 1137 CGAGTGAATCAGGGAATCTCTAGGAGATGGTCTTATTTACTGGAACACTGTAGC 1196
 QY 1081 CAGATGCTTACACAGATGATGATCAAGAAAGCCCGCTTACGACCCGATGATA 1140
 DB 1197 CAGATGCTTACACAGATGATGATCAAGAAAGCCCGCTTACGACCCGATGATA 1256
 QY 1141 AACATATCCCGGTACTGACAAACCATCACTTCCAGATGAGAGCTCTTACTGCA 1200

us-10-010-742-305.rng

XX Baker RP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AT, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI: 2002-172001/22.
DR P-PSDB; AAD83606.
XX
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumours
PT such as lung cancer, colon cancer, breast tumour, prostate tumour, rectal
PT tumour or liver tumour -
XX
XX
PS Claim 2; Figure 29; 359pp; English.
XX
XX The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumours, especially lung
CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. The PRO polypeptides are useful for stimulating the
CC proliferation of, or gene expression, in pericyte cells, for stimulating
CC the proliferation or differentiation of chondrocyte cells, for
CC stimulating the release of tumour necrosis factor-alpha from human blood,
CC for stimulating or inhibiting the proliferation of normal human dermal

CC
app

CC and in chromosome and gene mapping. ABK33556-ABK33657 represent human
CC PRO protein coding sequences of the invention.

Sequ

Query N

Matches

QY

Db

QY

Db

QY

DB

5

B

2

3

2

2.

1

2.

Q.

25

g